In primary cancer we found two enriched variants of BRAF, in melanoma and thyroid cancer, these are both variants that can be targeted by treatment [35] and therefore likely are selected against in development of metastatic cancer. This evidence concerns the gene BRAF and thyroid gland carcinoma.